in it for the money crypto Related searches

The tenth batch of national procurement officially opened, and the number of enterprises and varieties involved reached a record high. The tenth batch of centralized drug procurement organized by the state officially accepted the application materials of enterprises at 8: 00 this morning at No.398 Zhanyuan Road, Nanqiao New Town, Fengxian District, Shanghai. This centralized procurement involved 62 varieties and 263 product specifications, and the number of enterprises and varieties involved reached a record high. Among them, 33 enterprises competed for nine short-listed oral sustained-release formulations of sitagliptin. There are also a number of varieties that are billions in the market of public hospitals, such as doxorubicin hydrochloride liposome injection, cefoperazone injection, piperacillin injection, compound α -ketoacid oral sustained-release dosage form, norepinephrine injection and aspirin oral sustained-release dosage form. The sales scale in sample hospitals last year all exceeded 2 billion yuan. Hengrui Pharma, Kelun Pharmaceutical, Unacon and Zhengda Tianqing participated with many varieties. Note: According to the tenth batch of national adoption documents released before, the tenth batch of national adoption rules have changed a lot, such as canceling the protection mechanism of 50% price reduction and increasing the fuse recovery mechanism by 1.8 times, and the number of B-certified enterprises affects the number of final finalists.Market News: Little Red Book's net profit will exceed $1 billion in 2024.World Gold Council: The price of gold is expected to hit its best annual performance in more than 10 years. It is expected that there will be a positive but moderate growth next year. According to the report of the World Gold Council, the price of gold is expected to hit its best annual performance in more than 10 years, with an increase of 28% as of November. Behind this, the purchases of the central bank and investors offset the significant slowdown in consumer demand. Looking ahead, all eyes are focused on the impact of Trump's second term on the global economy. The current forecast of GDP, yield and inflation shows that gold will have a positive but much more moderate growth in 2025. The upward trend may benefit from a sharp drop in interest rates, an increase in volatility, or the continuous higher-than-average demand for gold by the central bank. On the contrary, higher long-term interest rates or weak demand for gold consumption may bring headwinds.

German Foreign Minister: Ukraine needs hard security.Morgan Stanley lowered Macy's target price from $17.00 to $16.00.The New Zealand dollar just broke through the 0.5800 mark against the US dollar, and the latest report was 0.5801, up 0.29% in the day; The Australian dollar just broke through the 0.6400 mark against the US dollar, and the latest report was 0.6401, up 0.51% in the day.

Spot platinum just broke through the $940.00/oz mark, and the latest price was $939.71/oz, up 0.45% in the day; The main force of Nymex platinum futures recently reported $955.7 per ounce, up 0.52% in the day.Jianfan Bio: The plasma separator was certified by the European Union MDR, and Jianfan Bio announced that Jianfan Blood Purification Company, a wholly-owned subsidiary, recently received a notice from the EU announcement agency that its plasma separator was certified by the European Union MDR in accordance with the EU Medical Devices Regulation 2017/745, and can be sold in EU countries and other countries that recognize the EU CE certification.Nanxin Technology: The equity of shareholders Shunwei Technology and its concerted actions changed to less than 5%. Nanxin Technology announced that the shareholders of the company Shunwei Technology and its concerted actions Hangzhou Shunying, Wuhan Shunying and Wuhan Shunhong reduced their holdings of the company's shares and passively diluted their equity, and the total number of shares held by the company changed from 30,843,800 shares to 21,272,800 shares, accounting for 7.2826% to 4.9999% of the company's total share capital, no longer.